Advocating for Patients with Rare Neurological Disease LEMS with Amy Grover Catalyst Pharmaceuticals

Published: April 13, 2021, 2:48 p.m.

Amy Grover, Director of Patient Advocacy, Catalyst Pharmaceuticals works primarily with patients suffering from Lambert-Eaton Myasthenic Syndrome LEMS an ultra-rare disease which is very similar to a larger rare disease myasthenia gravis MG. Working with the patient community and patient advocacy groups, Catalyst is providing support, tools and resources that for the most part have moved online during the pandemic.  As a seasoned patient advocate, Amy is aware of how unique each patient's journey is and how important their participation is in driving research.

@CatalystForRare #RareReason #rarediseases #LEMS #MG #patientadvocate

CatalystPharma.com

Download the transcript

Catalyst Pharma